Plaintiff The Tawnsaura Group, LLC ("Plaintiff") hereby alleges for its Complaint against Bio-Engineered Supplements and Nutrition, Inc. ("Defendant"), on personal knowledge as to its own activities and on information and belief as to the activities of others, as follows:

I. THE PARTIES

- 1. Plaintiff is a limited liability company organized and existing under the laws of Nevada, with a registered office at 50 West Liberty Street, Suite 1100, Reno, Nevada 89501.
- 2. Plaintiff is the owner and assignee of United States Patent No. 5,874,471 ("the '471 patent") titled "Orthomolecular Medical Use of L-Citrulline for Vasoprotection, Relaxative Smooth Muscle Tone and Cell Protection," and United States Patent No. 6,028,107 ("the '107 patent") titled "Orthomolecular Medical Use of L-Citrulline for Vasoprotection, Relaxative Smooth Muscle Tone and Cell Protection," and Plaintiff licenses the '471 patent and the '107 patent to more than one third-party and is in negotiations to license the patents to numerous other parties.
- 3. Upon information and belief, Defendant Bio-Engineered Supplements and Nutrition, Inc. is a corporation organized and existing under the laws of Florida with a principal place of business at 5901 Broken Sound Pkwy. in Boca Raton, Florida, 33478-2773.

II. JURISDICTION AND VENUE

- 4. This is an action for patent infringement arising under the patent laws of the United States, Title 35 of the United States Code. Accordingly, this Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1338, and 1367.
 - 5. Venue is proper in this district pursuant to 28 U.S.C. §§ 1391 and 1400.
- 6. This Court has personal jurisdiction over Defendant. Defendant, directly or through intermediaries (including distributors, retailers, and others), ships, distributes, offers for sale, sells, and advertises its nutritional supplement products in the United States, the State of California, and the Central District of California,

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

including the products "Amino X" and "Nitrix." Defendant has purposefully and voluntarily placed these products into the stream of commerce with the expectation that they will be purchased in the Central District of California.

III. THE DEFENDANT'S INFRINGING PRODUCTS

- 7. The label and/or advertisements for Defendant's product "Amino X" state that the product contains, <u>inter alia</u>, the ingredient "L-Citrulline (Micronized)," which "is known for its promotion of nitric oxide production."
- 8. The label and/or advertisements for Defendant's product "Nitrix" state that the product contains, <u>inter alia</u>, the ingredient "L-Citrulline," and "promotes vascularity and intense muscle pumps."
- 9. As set forth herein, these products infringe the claimed methods of the '471 patent and the '107 patent, and are therefore referred to herein as "the products that infringe the claimed methods."

IV. THE DEFENDANT'S INFRINGEMENTS

10. Defendant's employees, agents, representatives and other persons sponsored by or who endorse Defendant and Defendant's products in advertising and marketing activities, have taken, used, and orally administered the products that infringe the claimed methods which have the effect, without limitation, of increasing the plasma level of arginine in the persons taking the products from a low or normal fasting level to a level which is up to three times an average overnight fasting level and increasing the plasma concentration of arginine in the persons taking the products from a low or normal fasting concentration to a level which is up to three times an average overnight fasting arginine level of about 90 mu.mole per liter of plasma. These persons included persons who, without limitation, were in good health, were in a condition of increased or continuing brain or neural activities, or were in a condition of increased or Defendant has encouraged and/or is aware of these continuing muscular activities. persons' oral administration of the products that infringe the claimed methods for these purposes, and these persons are acting under Defendant's direction and control.

Therefore, Defendant practices the methods as set forth in the '471 patent and the '107 patent and is a direct infringer of the patents.

- also direct infringers of the '471 patent and the '107 patent, because they have taken, used, and orally administered the products that infringe the claimed methods which have the effect, without limitation, of increasing the plasma level of arginine in the persons taking the products from a low or normal fasting level to a level which is up to three times an average overnight fasting level and/or increasing the plasma concentration of arginine in the persons taking the products from a low or normal fasting concentration to a level which is up to three times an average overnight fasting arginine level of about 90 mu.mole per liter of plasma. These persons included persons who, without limitation, were in good health, were in a condition of increased or continuing muscular activities. Therefore, they practice the methods as set forth in the '471 patent and the '107 patent.
- 12. By way of example and without limitation, a consumer identified as "Killshot1" on http://forum.bodybuilding.com/showthread.php?t=142334301&page=1 posted a review regarding his/her use of Amino X, writing, in part, "i notice that i am able to achieve better pumps" after taking the product. Another consumer called "Sheldon Kelman" posted a review on http://www.amazon.com/BSN-Nitrix-Vaso-Muscular-Volumizer-Tablets/product-reviews/B000GP5HMU regarding his/her use of Nitrix, indicating "I get the pump everywhere and it's a lot cheaper than Viagra." These are just two of many end-users of the infringing products who have practiced the methods as set forth in the '471 patent and the '107 patent and are direct infringers of the patents.
- 13. Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that Defendant's labels and advertising for the products that infringe the claimed methods explain the elements and essential elements of the methods

- 14. Defendant's products that infringe the claimed methods are not suitable for non-infringing uses, and none of Defendant's labels or advertisements for the products disclose any uses for the products nor for the citrulline in those products that do not infringe upon the methods disclosed in the '471 patent and the '107 patent. The inclusion of the citrulline content in the products are, in fact, material to practicing the methods disclosed in the '471 patent and the '107 patent.
- 15. Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that Defendant has knowledge that its products that infringe the claimed methods are especially adapted by end-users of the products for the practicing of the methods disclosed in the '471 patent and '107 patent, and, indeed, Defendant encourages, urges, and induces the products' end-users to purchase and orally administer the products to practice those methods, and has done so in the past. Plaintiff intends to amend this complaint at the appropriate time to include more specific allegations pertaining to these facts.
- 16. Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that Defendant has intentionally and knowingly induced, encouraged, and urged end-users of the products that infringe the claimed methods to purchase and orally administer the products for the purpose, without limitation, of increasing the plasma level of arginine in the persons taking the products from a low or normal fasting level to a level which is up to three times an average overnight fasting level and increasing the plasma concentration of arginine in the persons taking the products from

11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 |

22

23

24

25

26

27

28

a low or normal fasting concentration to a level which is up to three times an average overnight fasting arginine level of about 90 mu.mole per liter of plasma, including by end-users who, without limitation, were in good health, were in a condition of increased or continuing brain or neural activities, or were in a condition of increased or continuing muscular activities. Plaintiff intends to amend this complaint at the appropriate time to include more specific allegations pertaining to these facts.

- Plaintiff believes facts to be ascertained during discovery in this matter 17. will demonstrate that Defendant had actual, first-hand knowledge of the '471 patent and the '107 patent as early as the time Defendant launched each of the products that infringe the claimed methods in the marketplace. By way of example and without limitation, Plaintiff believes such facts to be ascertained will include the fact that Defendant employs and engages sophisticated, experienced legal counsel with expertise in patent law, and that Defendant, through its counsel, conducts or should conduct due diligence on the potential for Defendant's products to infringe on patents and knew or should have known that the products that infringe the claimed methods actually infringe or could infringe on the '471 patent and '107 patent, but Defendant decided to infringe the patents anyway or ignored the risk of infringement. By way of further example and without limitation, Plaintiff believes such facts to be ascertained will include the fact that Defendant became aware of the '471 patent and '107 patent following the filing of lawsuits by Plaintiff against Defendant's competitors arising out of infringements by those competitors of the patents. Plaintiff intends to amend this complaint at the appropriate time to include more specific allegations pertaining to these facts.
- 18. In the alternative, Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that Defendant subjectively believed at the time Defendant launched each of the products that infringe the claimed methods in the marketplace that there is or was a high probability of the fact that patents existed that covered the use of citrulline as in the products and that Defendant took deliberate actions to avoid confirming that fact, including not conducting due diligence as to

potential patent infringements, and that Defendant therefore willfully blinded itself to the infringing nature of its sales of the products that infringe the claimed methods. Plaintiff intends to amend this complaint at the appropriate time to include more specific allegations pertaining to these facts.

- 19. At a minimum, Defendant will become aware of the '471 patent and the '107 patent at the time of the filing and service of this Complaint, yet Defendant will likely not cease its own direct infringement, nor what Plaintiff believes is Defendant's indirect infringement by contributory infringement or inducement of infringements by end-users, despite such knowledge. Plaintiff intends to amend this complaint at the appropriate time to include more specific allegations pertaining to these post-filing activities, based on facts to be ascertained during discovery in this matter.
- 20. The earliest exact date Defendant obtained knowledge of the '471 patent and the '107 patent is within the exclusive possession and control of Defendant. However, Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that Defendant specifically induces end-users to use its products, and particularly the citrulline component in the products, to promote nitric oxide production and "vascularity and intense muscle pumps," and Defendant knows and intends that end-users achieve those objectives by practicing the methods as set forth in the '471 and '107 patents. Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that this is why Defendant includes citrulline in its products for the purposes of improving of the health of end-users to increase the plasma level of arginine in end-users to a level from a low or normal fasting level to a level which is up to three times an average overnight fasting level, and improving the health of end-users to increase the plasma concentration of arginine in the subject to a level from a low or normal fasting concentration to a level which is up to three times an average overnight fasting arginine level of about 90 mu.mole per liter of plasma – and Defendant knows that end-users purchase and ingest the products, and particularly the citrulline content

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

of the products, for those purposes. Plaintiff intends to amend this complaint at the appropriate time to include more specific allegations pertaining to these facts. V.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

FIRST CAUSE OF ACTION

Infringement of U.S. Patent No. 5,874,471

- Plaintiff repeats and re-alleges the allegations of the foregoing paragraphs 21. of this Complaint as if fully set forth herein.
- Defendant has in the past and still is literally and directly infringing or 22. directly infringing under the doctrine of equivalents one or more claims of the '471 patent by making, using, selling, and offering for sale nutritional supplements embodying the patented invention, and will continue to do so unless enjoined by this Court.
- 23. The claims of the '471 patent infringed by Defendant include claims 1, 2, 20, 21, and 28.
- Examples of Defendant's direct infringement includes, without limitation, 24. the fact that Defendant's employees, agents, representatives and other persons sponsored by or who endorse Defendant and Defendant's products in advertising and marketing activities, have taken, used, and orally administered the products that infringe the claimed methods which have the effect, without limitation, of increasing the plasma level of arginine in the persons taking the products from a low or normal fasting level to a level which is up to three times an average overnight fasting level. These persons included persons who, without limitation, were in good health, were in a condition of increased or continuing brain or neural activities, or were in a condition of increased or continuing muscular activities. Defendant has encouraged and/or is aware of these persons' oral administration of the products that infringe the claimed methods for these purposes, these persons are acting under Defendant's direction and control. and therefore Defendant is directly practicing the methods set forth in the '471 patent.
- 25. Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that Defendant is also literally and indirectly or indirectly infringing

- under the doctrine of equivalents, through contributory and/or induced infringement, one or more claims of the '471 patent. Plaintiff intends to amend this First Cause of Action at the appropriate time once more specific facts pertaining to Defendant's acts of indirect infringement are ascertained.
- 26. Defendant's activities have been without express or implied license by Plaintiff.
- 27. Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that the infringement by Defendant has been and continues to be willful, and Plaintiff intends to amend this First Cause of Action at the appropriate time once more specific facts pertaining to Defendant's willful acts of infringement are ascertained.
- 28. As a result of Defendant's acts of infringement, Plaintiff has suffered and will continue to suffer damages in an amount to be proved at trial.
- 29. As a result of Defendant's acts of infringement, Plaintiff has been and will continue to be irreparably harmed by Defendant's infringements, which will continue unless Defendant is enjoined by this Court.
- 30. Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that Defendant's past infringement and/or continuing infringement has been deliberate and willful, and that this case is therefore an exceptional case, which warrants an award of treble damages and attorneys' fees in accordance with 35 U.S.C. § 285. Plaintiff intends to amend this First Cause of Action at the appropriate time once more specific facts pertaining to Defendant's deliberate and willful acts of infringement are ascertained.

VI. SECOND CAUSE OF ACTION

Infringement of U.S. Patent No. 6,028,107

31. Plaintiff repeats and re-alleges the allegations of the foregoing paragraphs of this Complaint as if fully set forth herein.

- 32. Defendant has in the past and still is literally and directly infringing or directly infringing under the doctrine of equivalents one or more claims of the '107 patent by making, using, selling, and offering for sale nutritional supplements embodying the patented invention, and will continue to do so unless enjoined by this Court.
- 33. The claims of the '107 patent infringed by Defendant include claims 1, 2, 15, and 16.
- 34. Examples of Defendant's direct infringement includes, without limitation, the fact that Defendant's employees, agents, representatives and other persons sponsored by or who endorse Defendant and Defendant's products in advertising and marketing activities, have taken, used, and orally administered the products that infringe the claimed methods which have the effect, without limitation, of increasing the plasma concentration of arginine in the persons taking the products from a low or normal fasting concentration to a level which is up to three times an average overnight fasting arginine level of about 90 mu.mole per liter of plasma. These persons included persons who, without limitation, were in good health, were in a condition of increased or continuing brain or neural activities, or were in a condition of increased or continuing muscular activities. Defendant has encouraged and/or is aware of these persons' oral administration of the products that infringe the claimed methods for these purposes, these persons are acting under Defendant's direction and control, and therefore Defendant is directly practicing the methods set forth in the '107 patent.
- 35. Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that Defendant is also literally and indirectly or indirectly infringing under the doctrine of equivalents, through contributory and/or induced infringement, one or more claims of the '107 patent. Plaintiff intends to amend this Second Cause of Action at the appropriate time once more specific facts pertaining to Defendant's acts of indirect infringement are ascertained.

- 14 15
- 16 17
- 18 19 20
- 21
- 23

- 24 25
- 26
- 27 28

- 36. Examples of Defendant's direct infringement includes, without limitation. the fact that Defendant's employees, agents, representatives and other persons sponsored by or who endorse Defendant and Defendant's products in advertising and marketing activities, have taken, used, and orally administered the products that infringe the claimed methods which have the effect, without limitation, of increasing the plasma concentration of arginine in the persons taking the products from a low or normal fasting concentration to a level which is up to three times an average overnight fasting arginine level of about 90 mu.mole per liter of plasma. These persons included persons who, without limitation, were in good health, were in a condition of increased or continuing brain or neural activities, or were in a condition of increased or continuing muscular activities. Defendant has encouraged and/or is aware of these persons' oral administration of the products that infringe the claimed methods for these purposes, these persons are acting under Defendant's direction and control, and therefore Defendant is directly practicing the methods set forth in the '107 patent.
- 37. Defendant's activities have been without express or implied license by Plaintiff.
- Plaintiff believes facts to be ascertained during discovery in this matter 38. will demonstrate that the infringement by Defendant has been and continues to be willful, and Plaintiff intends to amend this Second Cause of Action at the appropriate time once more specific facts pertaining to Defendant's willful acts of infringement are ascertained.
- 39. As a result of Defendant's acts of infringement, Plaintiff has suffered and will continue to suffer damages in an amount to be proved at trial.
- As a result of Defendant's acts of infringement, Plaintiff has been and will 40. continue to be irreparably harmed by Defendant's infringements, which will continue unless Defendant is enjoined by this Court.
- 41. Plaintiff believes facts to be ascertained during discovery in this matter will demonstrate that Defendant's past infringement and/or continuing infringement has

been deliberate and willful, and that this case is therefore an exceptional case, which warrants an award of treble damages and attorneys' fees in accordance with 35 U.S.C. § 285. Plaintiff intends to amend this Second Cause of Action at the appropriate time once more specific facts pertaining to Defendant's deliberate and willful acts of infringement are ascertained.

VII. PRAYER FOR RELIEF

WHEREFORE, Plaintiff prays for entry of judgment against Defendant as follows:

- 1. A declaration that Defendant has infringed the '471 patent and the '107 patent under 35 U.S.C. §§ 271 et seq.;
- 2. That injunctions, preliminary and permanent, be issued by this Court restraining Defendant, its respective officers, agents, servants, directors, and employees, and all persons in active concert or participation with each, from directly infringing the '471 patent and the '107 patent;
- 3. That Defendant be required to provide to Plaintiff an accounting of all gains, profits, and advantages derived by Defendant's infringement of the '471 patent and the '107 patent, and that Plaintiff be awarded damages adequate to compensate Plaintiff for the wrongful infringing acts by Defendant, in accordance with 35 U.S.C. § 284;
- 4. That, at the appropriate time after more specific facts pertaining to Defendant's acts of indirect, willful, and deliberate infringement are ascertained and this Complaint is amended to include such facts: (a) injunctions, preliminary and permanent, be issued by this Court restraining Defendant, its respective officers, agents, servants, directors, and employees, and all persons in active concert or participation with each, from indirectly infringing the '471 patent and the '107 patent; (b) Defendant be required to provide to Plaintiff an accounting of all gains, profits, and advantages derived by Defendant's indirect infringement of the '471 patent and the '107 patent; (c) Plaintiff be awarded damages adequate to compensate Plaintiff for the wrongful

- infringing acts by Defendant, in accordance with 35 U.S.C. § 284; and (d) the damages awarded to Plaintiff with regard to the '471 patent and the '107 patent be increased up to three times, in view of Defendant's willful infringement, in accordance with 35 U.S.C. § 284;
- 5. That, at the appropriate time after more specific facts pertaining to Defendant's acts of willful and deliberate infringement are ascertained and this Complaint is amended to include such facts, this case be declared to be exceptional in favor of Plaintiff under 35 U.S.C. § 285, and that Plaintiff be awarded its reasonable attorneys' fees and other expenses incurred in connection with this action;
- 6. That Plaintiff be awarded its interest and costs of suit incurred in this action;
 - 7. Compensatory damages;
 - 8. Punitive damages; and

Dated: November (4, 2012)

9. That Plaintiff be awarded such other and further relief as this Court may deem just and proper.

Respectfully submitted, NEWPORT TRIAL GROUP A Professional Corporation

By: Tyler L-Woods
Afforneys for Plaintiff

1	DEMAND FOR JURY TRIAL							
2	Pursuant to Federal Rule of Civil Procedure 38(b), Plaintiff hereby demands a							
3	jury trial for all issues in this case that properly are subject to a jury trial.							
4								
5	Respectfully submitted,							
6	NEWPORT TRIAL GROUP A Professional Corporation							
7								
8	Dated: November							
9	Attorneys for Plaintiff							
10								
11								
12								
13								
14								
15								
16								
17								
18								
19								
20								
21								
22								
23								
24								
25								
26								
27								
28								
- 11								

UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF CALIFORNIA

NOTICE OF ASSIGNMENT TO UNITED STATES MAGISTRATE JUDGE FOR DISCOVERY

This case has been assigned to District Judge Cormac J. Carney and the assigned discovery Magistrate Judge is Jean P. Rosenbluth.

The case number on all documents filed with the Court should read as follows:

SACV12- 1998 CJC (JPRx)

Pursuant to General Order 05-07 of the United States District Court for the Central

	agistrate Judge has been designated	to hear discovery related
All discovery related motion	s should be noticed on the calendar	of the Magistrate Judge
	NOTICE TO COUNSEL	
A copy of this notice must be served filed, a copy of this notice must be se	with the summons and complaint on all de erved on all plaintiffs).	fendants (if a removal action is
Subsequent documents must be file	d at the following location:	
Western Division 312 N. Spring St., Rm. G-8 Los Angeles, CA 90012	Southern Division 411 West Fourth St., Rm. 1-053 Santa Ana, CA 92701-4516	Eastern Division 3470 Twelfth St., Rm. 134 Riverside, CA 92501
Failure to file at the proper location will re	esult in your documents being returned to you.	

Fa

Case 8:12-cv-01998-CJC-JPR Document 1	Filed 11/15/12 Page 16 of 19 Page ID #:16				
Name & Address: NEWPORT TRIAL GROUP					
Tyler J. Woods (State Bar No. 232464)					
Richard H. Hikida (State Bar No. 196149)					
Scott J. Ferrell (State Bar No. 202091)					
895 Dove Street, Ste 425, Newport Beach, CA 92660	æ				
UNITED STATES I CENTRAL DISTRIC					
THE TAWNSAURA GROUP, LLC,	CASE NUMBER				
PLAINTIFF(S)	SACV 12 - 01998 CJC (JPRx)				
V.					
BIO-ENGINEERED SUPPLEMENTS AND					
NUTRITION, INC.					
	SUMMONS				
DEFENDANT(S).					
TO: DEFENDANT(S):					
A lawsuit has been filed against you.					
Within21 days after service of this summons on you (not counting the day you received it), you must serve on the plaintiff an answer to the attached ☑ complaint ☐ amended complaint ☐ amended complaint ☐ counterclaim ☐ cross-claim or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff's attorney, Newport Trial Group, whose address is 895 Dove Street, Suite 425, Newport Beach, CA 92660 If you fail to do so, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.					
	Clerk, U.S. District Court				
Dated: 11 15 1 2	Day Day Destaurant				
Dated.	Deputy Clerk				
	(Seal of the Court)				
[Use 60 days if the defendant is the United States or a United States agency, or is an officer or employee of the United States. Allowed 60 days by Rule 12(a)(3)].					
CV-01A (10/11 SUMM	IONS				

Name & Address: NEWPORT TRIAL GROUP Tyler J. Woods (State Bar No. 232464) Richard H. Hikida (State Bar No. 196149) Scott J. Ferrell (State Bar No. 202091) 895 Dove Street, Ste 425, Newport Beach, CA 92660					
CENTRAL DISTRIC	DISTRICT COURT CT OF CALIFORNIA				
THE TAWNSAURA GROUP, LLC,	CASE NUMBER				
PLAINTIFF(S) v.	SACV 12 - 01998 CJC (JPRx)				
BIO-ENGINEERED SUPPLEMENTS AND NUTRITION, INC.	SUMMONS				
DEFENDANT(S).					
A lawsuit has been filed against you. Within 21 days after service of this summon must serve on the plaintiff an answer to the attached counterclaim □ cross-claim or a motion under Rule 12 or motion must be served on the plaintiff's attorney, New 895 Dove Street, Suite 425, Newport Beach, CA 92660 judgment by default will be entered against you for the reyour answer or motion with the court.	2 of the Federal Rules of Civil Procedure. The answer wport Trial Group , whose address is . If you fail to do so,				
Dated: 11 15 12	Clerk, U.S. District Court DENISE VO Deputy Clerk (Seal of the Court)				
[Use 60 days if the defendant is the United States or a United States agency, or is an officer or employee of the United States. Allowed 60 days by Rule 12(a)(3)].					
CV-01A (10/11 SUMMO	DNS				

UNITED STATES DISTRICT COURT, CENTRAL DISTRICT OF CALIFORNIA CIVIL COVER SHEET

I (a) PLAINTIFFS (Check box if you are representing yourself []) THE TAWNSAURA GROUP, LLC,						DEFEND. BIO-EN		SUPP	LEME	NTS AND NUTRI	TION, INC.		
(b) Attorneys (Firm Name, Address and Telephone Number. If you are represent yourself, provide same.) NEWPORT TRIAL GROUP, 895 Dove Street, Suite 425, Newport Beach, 92660 Tel; (949) 706-6464 Fax (949)706-6469						Attorneys	(If Known)						
II. BA	SIS OF JURISDICTION	N (Place	e an X in one box only.)		III. CITIZENSHIP OF PRINCIPAL PARTIES - For Diversity Cases Only (Place an X in one box for plaintiff and one for defendant.)								
☐ 1 U.S. Government Plaintiff ☐ 3 Federal Question (U.S. Government Not a Party)					PTF DEF Citizen of This State				•	PTF □ 4	DEF □ 4		
□ 2 U	S. Government Defendan	t 😿 4	Diversity (Indicate Citize of Parties in Item III)	enship	Citizen of Another State			□2	□ 2	Incorporated and Principal Place 5 5 5 of Business in Another State			™ 5
					Citizen or Subje	ect of a Fore	eign Country	□ 3	□ 3	Foreign Nation	-	□6	□6
▼ 1 C	IV. ORIGIN (Place an X in one box only.) 1 Original Proceeding State Court Appellate Court Reopened From Proceeding State Court Appellate Court Reopened From Proceeding State Court Reopened From												
	QUESTED IN COMPL. S ACTION under F.R.C		JURY DEMAND: 12	res ∟						AINT: § TBD			
					···								
			S. Civil Statute under which	ch you	are filing and wr	ite a brief st	atement of ca	use. D	o not c	ite jurisdictional st	atutes unless div	ersity.))
	5 USC §§271, et seq; 35 1 ATURE OF SUIT (Plac												
****		t an A	in one box only.)								I		
100,000,000	THER STATUTES		CONTRACT	100000	TORTS		TORTS		25.2	PRISONER	LAE	, 1.2, 1.12.	1975 (). 1975 ().
	State Reapportionment Antitrust		Insurance Marine		RSONAL INJURY Airplane		PERSONAL PROPERTY		Charles San	PETITIONS Motions to	□ 710 Fair La	bor Sta	ındards
	Banks and Banking		Miller Act		Airplane Produc	. 1	Other Fraud		□ 310		Act □ 720 Labor/I	/Jomt	
	Commerce/ICC	□ 140	Negotiable Instrument		Liability	□ 371	Truth in Ler			Habeas Corpus	Relatio		
	Rates/etc.	□ 150	Recovery of	□ 320	Assault, Libel &	□ 380	Other Person			General	☐ 730 Labor/1	Agmt.	
	Deportation		Overpayment &	rii 330	Slander Fed. Employers	,				Death Penalty	Reporti		
□ 470	Racketeer Influenced	l	Enforcement of	L 330	Liability	□ 385	Property Da		□ 540		Disclos		
	and Corrupt Organizations	□ 151	Judgment Medicare Act	□ 340	Marine	and a state of the state of	Product Lial		□ 650	Other Civil Rights	 □ 740 Railwa; □ 790 Other I 		r Act
□ 480	~	ŧ	Recovery of Defaulted	□ 345	Marine Product		Appeal 28 U			Prison Condition			
	Cable/Sat TV		Student Loan (Excl.	D 250	Liability		158			ORFEITURE /	☐ 791 Empl. I		.
	Selective Service		Veterans)		Motor Vehicle Motor Vehicle	□ 423	Withdrawal	28	100	PENALTY	Securit		
□ 850	Securities/Commodities/	□ 153		C 222	Product Liabilit	v I	USC 157			Agriculture	PROPERT	/ RIGI	HTS
□ 07 <i>E</i>	Exchange	ŀ	Overpayment of	□ 360	Other Personal	, l C	IVIL RIGHTS	S	□ 62 0	Other Food &	□ 820 Соругія	ghts	
□ 6/3	Customer Challenge 12 USC 3410	□ 160	Veteran's Benefits Stockholders' Suits		Injury	f	Voting Employmen	.	ITI 625	Drug Drug Related	№ 830 Patent □ 840 Tradem	a=1.	
□ 890			Other Contract	Li 362	Personal Injury- Med Malpractic		Housing/Ac		02.5	Seizure of	SOCIAL S	1.41.1	ITV
	Agricultural Act	1	Contract Product	□ 365	Personal Injury-	- 1	mmodations				□ 861 HIA (1	-	
	Economic Stabilization		Liability		Product Liabilit		Welfare			881	□ 862 Black I		23)
	Act		Franchise	□ 368	Asbestos Persor	nal 🗆 445	American w	ith	□ 630	Liquor Laws	□ 863 DIWC/	DIWW	7
	Environmental Matters	,	REAL PROPERTY		Injury Product		Disabilities			R.R. & Truck	(405(g)	•	
	Energy Allocation Act		Land Condemnation	"	Liability MMIGRATION	- AAC	Employmen			Airline Regs	□ 864 SSID T		/I
	Freedom of Info. Act Appeal of Fee Determi-		Foreclosure Rent Lease & Ejectment		Naturalization	□ 446	American w Disabilities		□ 000	Occupational Safety /Health	□ 865 RSI (40 FEDERAL 1		TITTO
700 ب	nation Under Equal		Torts to Land	- ··-	Application		Other		□ 690	-	B70 Taxes (
	Access to Justice		Tort Product Liability	□ 463	Habeas Corpus-	□ 440	Other Civil		0,0		or Defe		
□ 950	Constitutionality of		All Other Real Property	<u> </u>	Alien Detainee	[Rights	ļ			□ 871 IRS-Th		
	State Statutes		- •	□ 465	Other Immigrat: Actions	on	•				USC 76		•
		 				······································				**************************************			
	· · · · · · · · · · · · · · · · · · ·												

FOR OFFICE USE ONLY: Case Number: SACV 12 - 01998 CJC (JPRx)

AFTER COMPLETING THE FRONT SIDE OF FORM CY-71, COMPLETE THE INFORMATION REQUESTED BELOW.

CV-71 (05/08)

Case 8:12-cv40/1900-STATEAPINSTIRICTURGONRT, CENTURALI/10/6/12/1CP20JeCASLINFORMIAPage ID #:19 CIVIL COVER SHEET

VIII(a). IDENTICAL CASES: Ha	s this action been pr	eviously filed in this court an	nd dismissed, remanded or closed? ♥No □ Yes				
VIII(b). RELATED CASES: Have If yes, list case number(s):	e any cases been pre	eviously filed in this court tha	at are related to the present case? ♥ No □ Yes				
□ B. □ C.	Arise from the same Call for determinati For other reasons w	e or closely related transaction on of the same or substantiall ould entail substantial duplic	ons, happenings, or events; or ly related or similar questions of law and fact; or ration of labor if heard by different judges; or the same one of the factors identified above in a, b or c also is present.				
IX. VENUE: (When completing the	-		• •				
			f other than California; or Foreign Country, in which EACH named plaintiff resides. this box is checked, go to item (b).				
County in this District:*		THE CONTROL OF THE CO	California County outside of this District; State, if other than California; or Foreign Country				
			THE TAWNSAURA GROUP, LLC - Washoe County, Nevada				
(b) List the County in this District; Check here if the government, it	California County o s agencies or emplo	utside of this District; State it	f other than California; or Foreign Country, in which EACH named defendant resides. If this box is checked, go to item (c).				
County in this District:*			California County outside of this District; State, if other than California; or Foreign Country				
			BIO-ENGINEERED SUPPLEMENTS AND NUTRITION, INC Palm Beach County, FL				
(c) List the County in this District; (Note: In land condemnation ca			f other than California; or Foreign Country, in which EACH claim arose.				
County in this District:*			California County outside of this District; State, if other than California; or Foreign Country				
Plaintiff's Claim - Orange Count	y, CA						
* Los Angeles, Orange, San Bernar Note: In land condemnation cases, us	dino, Riverside, Vo	entura, Santa Barbara, or S tract of land involved	San Luis Obispo Counties				
X. SIGNATURE OF ATTORNEY (OR PRO PER):	JUJ We	Date November 2 2012				
or other papers as required by lav	 This form, approve 	ed by the Judicial Conference	mation contained herein neither replace nor supplement the filing and service of pleadings e of the United States in September 1974, is required pursuant to Local Rule 3-1 is not filed ing the civil docket sheet. (For more detailed instructions, see separate instructions sheet.)				
Key to Statistical codes relating to So	cial Security Cases:						
Nature of Suit Code	Abbreviation	Substantive Statement of	f Cause of Action				
861	НІА	All claims for health insurance benefits (Medicare) under Title 18, Part A, of the Social Security Act, as amended. Also, include claims by hospitals, skilled nursing facilities, etc., for certification as providers of services under the program. (42 U.S.C. 1935FF(b))					
862	BL	All claims for "Black Lung" benefits under Title 4, Part B, of the Federal Coal Mine Health and Safety Act of 1969. (30 U.S.C. 923)					
863	DIWC	All claims filed by insured workers for disability insurance benefits under Title 2 of the Social Security Act, as amended; plus all claims filed for child's insurance benefits based on disability. (42 U.S.C. 405(g))					
863	DIWW	All claims filed for widows or widowers insurance benefits based on disability under Title 2 of the Social Security Act, as amended. (42 U.S.C. 405(g))					
864	SSID	All claims for supplementa Act, as amended.	al security income payments based upon disability filed under Title 16 of the Social Security				
865	RSI	All claims for retirement (old age) and survivors benefits under Title 2 of the Social Security Act, as amended. (42 U.S.C. (g))					

CV-71 (05/08) CIVIL COVER SHEET Page 2 of 2